Suppr超能文献

用于评估肠道微生物群的熊去氧胆酰对氨基苯甲酸的基础研究。

Basic studies on ursodeoxycholyl-para-aminobenzoic acid for evaluation of intestinal microflora.

作者信息

Takahashi M, Maeda Y, Tashiro H, Akazawa F, Okajima M, Yoshioka S, Matsugu Y, Toyota K, Masaoka Y

机构信息

Dept. of Surgery, Chugoku Rosai Hospital, Hiroshima, Japan.

出版信息

Scand J Gastroenterol. 1991 Jun;26(6):577-88. doi: 10.3109/00365529109043631.

Abstract

A newly synthesized conjugate of ursodeoxycholic acid with para-aminobenzoic acid (PABA) was investigated to determine its suitability for evaluation of enteric bacteria. This compound, PABA-UDCA, was deconjugated by cholylglycine hydrolase to release free PABA, whereas it was completely resistant to deconjugation by pancreatic and intestinal mucosal enzymes. In bacteriologic experiments almost all the microorganisms that split glycocholic acid deconjugated PABA-UDCA. In rat experiments urinary excretions of PABA were measured during 6 h after oral administration of 10 mg PABA-UDCA (PABA-UDCA administration test). Ten control rats excreted 338.5 +/- 13.8 micrograms (mean +/- SE) of PABA; 10 rats with intestinal stagnant loop excreted more (673.6 +/- 70.2 micrograms; P less than 0.01); whereas 10 rats in each of 7 groups pretreated with oral administration of various antibiotics excreted less (P less than 0.001; polymixin B + tinidazole, 14.0 +/- 2.5 micrograms; polymixin B, 224.9 +/- 23.5 micrograms; tinidazole, 42.7 +/- 8.6 micrograms; kanamycin, 50.3 +/- 5.8 micrograms; clindamycin, 57.4 +/- 7.4 micrograms; vancomycin, 70.4 +/- 8.5 micrograms; and paromomycin, 160.4 +/- 16.4 micrograms). This result was reflected by the bacterial mean count of feces. In the PABA-UDCA administration test, after 2 months of feeding with different diets, rats with high-fiber diet (n = 10) excreted less PABA in urine (70.9 +/- 15.9 micrograms; P less than 0.001) than rats on a control diet (n = 10) and a high-protein-high-fat diet (n = 10) (288.9 +/- 34.5 micrograms and 386.7 +/- 61.2 micrograms, respectively). Fecal bacteriologic status was consistently altered. In human volunteers 250 mg PABA-UDCA was tested. Amounts of PABA excreted in urine during 6 h after dosing were 21.11 +/- 2.02 mg in controls (n = 5) and 12.20 +/- 1.01 mg in the group treated with polymixin B plus tinidazole (n = 5; P less than 0.01). No adverse effect was observed. These basic studies indicate that this compound is likely to offer a simple and rapid method for evaluation of the intestinal microorganisms without use of radioisotopes or expensive, special equipment.

摘要

研究了一种新合成的熊去氧胆酸与对氨基苯甲酸(PABA)的共轭物,以确定其用于评估肠道细菌的适用性。这种化合物,即PABA-UDCA,可被胆酰甘氨酸水解酶解共轭以释放游离PABA,而它对胰腺和肠粘膜酶的解共轭作用具有完全抗性。在细菌学实验中,几乎所有能分解甘氨胆酸的微生物都能使PABA-UDCA解共轭。在大鼠实验中,口服10mg PABA-UDCA后6小时内测量PABA的尿排泄量(PABA-UDCA给药试验)。10只对照大鼠排泄338.5±13.8微克(平均值±标准误)的PABA;10只患有肠道淤滞环的大鼠排泄量更多(673.6±70.2微克;P<0.01);而7组中每组10只经口服各种抗生素预处理的大鼠排泄量较少(P<0.001;多粘菌素B+替硝唑,14.0±2.5微克;多粘菌素B,224.9±23.5微克;替硝唑,42.7±8.6微克;卡那霉素,50.3±5.8微克;克林霉素,57.4±7.4微克;万古霉素,70.4±8.5微克;巴龙霉素,160.4±16.4微克)。这一结果反映在粪便细菌平均计数上。在PABA-UDCA给药试验中,用不同饮食喂养2个月后,高纤维饮食组(n=10)的大鼠尿中排泄的PABA比对照饮食组(n=10)和高蛋白高脂肪饮食组(n=10)少(分别为70.9±15.9微克;P<0.001)(分别为288.9±34.5微克和386.7±61.2微克)。粪便细菌学状态持续改变。在人体志愿者中测试了250mg PABA-UDCA。给药后6小时内,对照组(n=5)尿中排泄的PABA量为21.11±2.02mg,多粘菌素B加替硝唑治疗组(n=5)为12.20±1.01mg(P<0.01)。未观察到不良反应。这些基础研究表明,该化合物可能提供一种简单快速的方法来评估肠道微生物,而无需使用放射性同位素或昂贵的特殊设备。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验